• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

'R&D myth' Hanmi Pharm couldn't avoid 'management dispute'

박슬기 기자

seulgi@fntimes.com

기사입력 : 2024-09-04 18:42 최종수정 : 2024-09-04 20:53

Lim Jong-Yoon, Hanmi Pharm's Inside Director, Rejected CEO Appointment Proposal
Under Park Jae-hyun, Hanmi Pharmaceutical strengthens independent management
Conflict between brother vs. mother-daughter intensifies...company's competitiveness may be compromised

Hanmi Pharmaceuticals Headquarters / Photo source=Hanmi Pharmaceuticals

Hanmi Pharmaceuticals Headquarters / Photo source=Hanmi Pharmaceuticals

[Korea Financial Times, Park seulgi] The dispute over management rights between the mother and daughter of Hanmi Pharmaceutical Group and the brother is getting fiercer. On the 2nd, the agenda to appoint Lim Jong-yoon, the eldest son of the founder, as the CEO was rejected. As a result, the conflict between Hanmi Pharmaceutical on the mother and daughter side, which declared independent management, and Hanmi Science, the holding company on the brother side, is expected to intensify. However, there are also concerns about damaging corporate competitiveness due to long-term management disputes.

According to the industry on the 3rd, Hanmi Pharmaceutical held a board meeting at Hanmi Tower in Songpa-gu, Seoul, the morning before and voted on the appointment of director Lim Jong-yoon. Lim Jong-yoon, an in-house director, resigned CEO Park Jae-hyun and posted an agenda that he would step up to the position, but failed to pass. Industry experts say that it was a predicted result. Among the composition of Hanmi Pharmaceutical's board of directors, there are seven people on the mother's side and three people on the brother's side.

After winning the group's management dispute earlier this year, brothers Lim Jong-yoon and Lim Jong-hoon appointed four new directors, including themselves, to compete 6-4. At that time, Shin Dong-guk, chairman of Hanyang Precision, the largest shareholder of Hanmi Science, joined hands with the brothers, and later formed a coalition with Chairman Song Young-sook and Vice Chairman Lim Joo-hyun, and the topography of the board of directors leaned toward the mother and daughter.

According to the results of the board of directors' meeting, it is expected that the strengthening of the independent management system declared by CEO Park Jae-hyun will be supported. Earlier, CEO Park announced on the 28th that he would establish a human resources team and a legal team at Hanmi Pharmaceutical, and on the 29th that Hanmi Pharmaceutical would conduct its own independent management, not a subsidiary of Hanmi Science. Currently, Hanmi Pharmaceutical is taking steps to transfer its personnel and legal affairs, which was entrusted to the holding company, to the new organization.

Earlier, Hanmi Science CEO Lim Jong-hoon, the second son of the founder, demoted Park from president to executive vice president after he announced his intention to run the company independently. Afterward, Lim Jong-yoon, director, requested a board meeting to review the proposal to make him head of Hanmi Pharm, but it was rejected.

In this regard, “Hanmi Pharm's unilateral independence undermines shareholder value,” Lim said, adding that he would consider holding an extraordinary general meeting to replace the board and management.

He also raised the possibility of a secret deal in the board process. “I expected us to be 6-4 in favor, but two members changed their opinions, and I think there was a secret agreement in the process,” Lim said, adding, ”If there was a secret agreement, we will actively respond to it.”

The protracted battle between the brothers and the mother and the daughter over the holding company and its core affiliate, Hanmi Pharmaceutical, has raised concerns about damaging corporate competitiveness. The company is currently facing a number of challenges, including the development of new drugs, domestic sales, and exports, and they are spending all their time squabbling over the business when they could be working together.

“I am concerned that both Hanmi Pharm and Hanmi Science will hold shareholder meetings in the midst of Hanmi Group's infighting. What a waste of time they are wasting not being able to discuss new drugs,” said director Lim. ”The mother-daughter team will continue to try to add board members because they cannot control the company through their shareholding, and until they do, the management dispute will continue.”

Park seulgi (seulgi@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

유통·부동산 다른 기사

1 ‘제약’ 벗고 ‘뷰티’ 입는다…동국제약 권병훈, ‘DK센텔리안’ 연착륙 시험대 동국제약이 창사 이래 최초로 연간 매출 1조 원 돌파를 앞두고 ‘DK센텔리안(DK Centellian)’으로 사명 변경을 추진한다. 1982년 현재 상호 도입 이후 44년 만의 ‘제약’ 명칭 폐기로, 오너 3세 권병훈 이사 주도 아래 뷰티·헬스케어 중심의 체질 전환에 나섰다. 외형 성장 이면에 가중된 원가 부담에 따른 수익성 방어와 해외 시장 안착이 권 이사의 핵심 과제로 부각되고 있다.44년 만에 ‘제약’ 떼내…권병훈이 주도하는 화장품 밸류체인 내재화19일 제약바이오업계에 따르면 동국제약은 오는 27일 임시 주주총회를 통해 사명 변경을 추진한다. 기존의 ‘동국제약’을 ‘디케이센텔리안(DK센텔리안)’으로 바꾸는 내용의 ‘정관 일부 변경 2 HLB그룹, 미래전략·AX 조직 신설…진양곤 의장은 그룹 전략 총괄 집중 HLB그룹이 미래 성장동력 확보와 인공지능(AI) 기반 경영 혁신을 위한 조직개편 및 정기 임원 인사를 단행했다. 회사는 그룹 컨트롤타워 내 미래전략부문과 AX(AI 전환)혁신팀을 신설하는 한편, 승진 임원 22명 중 절반을 40대 젊은 인재로 발탁하며 세대교체와 실행력 강화에 나섰다.HLB그룹은 그룹 중장기 전략의 수립과 실행을 총괄하는 미래전략부문과 AI 기반 경영 혁신을 주도할 AX혁신팀을 새롭게 신설하고, 역량 있는 차세대 인재들을 주요 경영진으로 전진 배치했다고 19일 밝혔다.이번 인사는 급변하는 글로벌 경영환경에 선제적으로 대응하고 그룹 차원의 전략적 의사결정과 실행 속도를 높이는 데 초점을 맞췄다. 특히 전체 승진 대상 3 롯데하이마트, 수험생 겨냥 ‘하이마트 수능패스’…IT가전 할인 행사 롯데하이마트가 대학수학능력시험을 마친 수험생과 학생들을 대상으로 노트북, 태블릿, 스마트폰 등 IT가전 할인 행사에 나선다. 새 학기 준비와 수능 이후 여가 활동에 필요한 제품을 중심으로 할인과 사은품 증정 혜택을 제공한다.롯데하이마트는 19일부터 전국 매장에서 ‘하이마트 수능패스’ 행사를 진행한다고 밝혔다.먼저 조립 PC와 노트북 행사상품 구매 고객 선착순 300명에게 최대 10만원 상당의 모니터 또는 마우스를 증정한다. 자체 브랜드(PB) ‘플럭스(PLUX)’ 조립 PC 행사상품 구매 시 주연 24인치 게이밍 모니터를 제공하며, LG전자 ‘그램 프로’, 레노버 ‘슬림’, ‘LOQ 게이밍’, 에이수스 ‘비보북’, ‘TUF 게이밍’ 등 노
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[카드뉴스] 성북동 언덕길, 만해의 집을 만나다
[카드뉴스] 약재 향 따라 걷는 서울약령시
[그래픽 뉴스] ‘순대’가 경제용어라고? 순(純)대외자산, 한국의 진짜 해외자산은 얼마일까?
[그래픽 뉴스] ISA 대개편! 나에게 유리한 계좌는?
[그래픽 뉴스] 미국 증시 새로운 키워드 'MANGOS'

FT도서

더보기